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A B S T R A C T
The Brugada syndrome (BS) is a relative ne� �lini�al entity �hara�teri�ed �y �om�
plete or in�omplete right �undle �ran�h �lo�k (RBBB) and ST�segment elevation in 
leads V1 through V3 on surfa�e ele�tro�ardiogram (ECG), the a�sen�e of stru�tural 
heart disease, and a high risk of atrial fi�rillation, ventri�ular ta�hy�ardia/ventri�ular 
fi�rillation (VT/VF) and sudden �ardia� death (SCD). The syndrome is �onsidered 
responsi�le for 4�12% of all sudden deaths and at least 20% of deaths in patients �ith 
stru�turally normal hearts. BS typi�ally manifests �ith syn�ope and �ardia� arrest, 
o��urring in the third and fourth de�ade of life, and usually at rest or during sleep. 
Although the average age at time of first diagnosis or SCD is 40 years, the BS has 
�een des�ri�ed in a �ide range of ages. The �lini�al phenotype is 8 to 10 times more 
prevalent in males than in females. Sin�e its initial re�ognition, an ex�eptional progress 
regarding the pathophysiology and management of the disease has �een performed.
Several �andidate genes have �een identified in patients �ith BS. The SCN5A gene 
(�hromosome 3p21) en�oding for the �ardia� sodium �hannel (INa) �as the first gene 
linked to BS. Over 100 mutations of the SCN5A gene have �een identified up to no�. 
Loss of fun�tion of the INa �hannel resulting from �hanges in the fun�tional properties 
(gating) of the mutant Na �hannels, or failure of expression in the sar�olemma (traffi�k�
ing) is the major effe�t of SCN5A gene mutations. Ιn a large family �ith BS phenotype 
�here a SCN5A mutation �as ex�luded as the �andidate gene, a se�ond distin�t lo�us 
(�hromosome 3p24) linked to the gly�erol�3�phosphate dehydrogenase 1�like gene 
(GPD1L) �as identified. GPD1L mutations have �een sho�n to result in a redu�tion 
of INa. The third and fourth genes asso�iated �ith the BS are the α1� (CACNA1C) and 
β� (CACNB2b) su�units of the L�type �ardia� �al�ium �hannel. BS is a disease that 
manifests in adulthood �ith a very in�omplete penetran�e and a high proportion of 
mutation �arriers remain asymptomati�, and therefore, the value of geneti� analysis for 
reprodu�tive �ounselling is less o�vious than in other �onditions asso�iated �ith SCD.
Up to date, the diagnosis of Brugada ECG pattern is stri�tly �ased on the re�om�
mendations of the Se�ond Consensus Conferen�e on BS. A��ording to this report, 
three types of ECG repolari�ation patterns in right pre�ordial leads (V1�V3) have �een 
re�ogni�ed. Type 1 is diagnosti� of BS and is �hara�teri�ed �y a �oved ST�segment 
elevation ≥2 mm follo�ed �y a negative T �ave in more than one right pre�ordial leads. 
Type 2 ST�segment elevation displays a saddle�a�k �onfiguration �ith a high takeoff 
ST�segment elevation of ≥2 mm, a trough displaying ≥ 1 mm ST elevation, and either 
a positive or �iphasi� T �ave. Type 3 has either a saddle�a�k or �oved appearan�e 
�ith an ST�segment elevation of ≤1 mm. The ECG features of Brugada syndrome 
are often �on�ealed requiring a pharma�ologi�al �hallenge (sodium �hannel �lo�king 
CARDIAC ARRHYTHMIA UPDATE
Second Department of Cardiology, 
Evagelismos General Hospital of 
Athens, Athens, Greece
HOSPITAL CHRONICLES 2012, VOLUME 7, SUPPLEMENT 1: 143–145
Corresponding author:
Konstantinos P. Letsas, MD, FESC
Se�ond Department of Cardiology, 
Evangelismos General Hospital of 
Athens




KEY WORDS: Brugada syndrome; 
ventricular tachyarrhythmias; sudden 
cardiac death; implantable cardioverter 
defibrillator
AbbreviAtion
BS = Brugada syndrome
ECG = ele�tro�ardiogram
EPS = ele�trophysiology study
ICD = implanta�le �ardioverter 
defi�rillator
RBBB = right �undle �ran�h �lo�k
SCD = sudden �ardia� death
VF = ventri�ular fi�rillation
VT = ventri�ular ta�hya�rdia
Confli�t of Interest: none de�lared
144
HOSPITAL CHRONICLES 2010, VOLUME 7, SUPPLEMENT 1: «ATHENS CARDIOLOGY UPDATE 2012»
test) �ith a Class I antiarrhythmi� agent (ajmaline, ajmaline, 
pro�ainamide, fle�ainide) to unmask the �hara�teristi� ST�
segment elevation in the right pre�ordial leads. The diagnosis 
of BS is after�ards �onsidered positive �hen the �aseline type 
2 or type 3 ST�segment elevation �onverted to the diagnosti� 
type 1 pattern (ST�segment elevation ≥2 mm). Previous stud�
ies have demonstrated that ECG re�ordings (leads V1 and 
V2) performed at a higher inter�ostal spa�e exhi�it a higher 
sensitivity �ompared to the standard positions in dete�ting 
the type 1 ECG pattern of BS. Additionally, the type 1 ECG 
pattern re�orded only at the higher inter�ostal spa�e sho�ed a 
similar prognosti� value for su�sequent �ardia� events as that 
re�orded at the standard spa�e. In a re�ent report, individuals 
�ith ECGs displaying only one diagnosti� right pre�ordial lead 
(lead V1 or V2) had a similar �lini�al profile and arrhythmi� risk 
as BS patients �ith ECGs displaying more than one diagnosti� 
right pre�ordial lead. Revision of the Consensus �riteria should 
�e therefore �onsidered.
The sensitivity and spe�ifi�ity of sodium �hannel �lo�k�
ing test varies signifi�antly. The sensitivity and spe�ifi�ity of 
fle�ainide, estimated among SCN5A�positive pro�ands and 
their family mem�ers, �ere 77% and 80%, and its positive 
and negative predi�tive values 96% and 36%, respe�tively. In a 
similar study, the sensitivity, spe�ifi�ity, and positive and nega�
tive predi�tive values of ajmaline �hallenge among 35 geneti� 
�arriers �ere 80%, 94.4%, 93.3%, and 82.9%, respe�tively. On 
the �ontrary, pro�ainamide exhi�its a less use�depended �lo�k 
of the fast INa �hannel, and therefore is less effe�tive �ompared 
to all other agents. It has to �e mentioned that a negative INa 
�lo�king test does not ex�lude the presen�e of a SCN5A muta�
tion. Apart from the sodium �hannel �lo�kers, several other 
�onditions or drugs may un�over a Brugada�type ECG pattern 
in�luding vagotoni� agents, α�adrenergi� agonists, β�adrenergi� 
�lo�kers, tri�y�li� antidepressants, glu�ose�indu�ed insulin 
se�retion, fever, hyperkalemia, hypokalemia, hyper�al�emia, 
al�ohol and �o�aine toxi�ity have �een sho�n to unmask or 
modulate the �hara�teristi� ST�segment elevation in right 
pre�ordial leads.
BS is definitively diagnosed �hen a spontaneous or drug�
indu�ed type 1 ECG pattern is o�served in more than one 
right pre�ordial lead in �om�ination �ith one or more of 
the follo�ing: (i) do�umented VF, polymorphi� ventri�ular 
ta�hy�ardia (VT), (ii) family history of SCD (<45 years old), 
(iii) �oved�type ECGs in family mem�ers, (iv) indu�i�ility of 
VT �ith programmed ele�tri�al stimulation, and (v) syn�ope 
or no�turnal agonal respiration. The ECG features of BS are 
dynami� and often masked, and thus it is relatively diffi�ult 
to estimate the true in�iden�e of the disease in the general 
population. Furthermore, the o��urren�e of Brugada�type 
ECG pattern is strongly related to age. Previous studies have 
demonstrated that Brugada sign �egins to appear during junior 
high s�hool and in�reases until late adulthood. The frequen�y 
of Brugada sign varies signifi�antly among ethni� populations 
(0.012�6.1%).
The pathophysiology of the BS is only partially resolved. 
The seminal �ork �y Ant�elevit�h and �olleagues had �learly 
demonstrated regional heterogeneities in a�tion potential 
�hara�teristi�s �et�een the right and left ventri�les, as �ell 
among epi�ardium, mid�myo�ardium and endo�ardium. A loss 
of the a�tion potential dome at the epi�ardium �ut not at the 
endo�ardium �reates a transmural voltage gradient that may 
�e responsi�le for the ST�segment elevation. This me�hanism 
properly a��ounts for not only the ST�segment elevation �ut 
also the premature ventri�ular �ontra�tion (phase 2 reentry) 
and reentrant su�strate for VF in BS. Up to no�, t�o prin�
�ipal me�hanisms are thought to �e responsi�le for BS. The 
repolari�ation disorder hypothesis states that a non�uniform 
a��reviation of the right ventri�ular a�tion potential, related 
to differen�es in expression of ion �hannels, �auses the BS 
features. The depolari�ation disorder hypothesis states that 
the redu�tion in INa results in �ondu�tion delay in the right 
ventri�ular outflo� tra�t a�tion potential in respe�t to the right 
ventri�le a�tion potential. Overlap �et�een these me�hanisms 
may �e present.
Risk stratifi�ation of su�je�ts �ith BS remains pro�lemati�. 
Several �lini�al, ECG and ele�trophysiologi�al parameters 
have �een proposed to identify high risk patients �ith BS. 
Male sex is a risk fa�tor for SCD in BS. Familial forms of the 
disease do not �arry a �orse prognosis than isolated �ases. 
Therefore, a family history of BS does not predi�t a �orse 
out�ome. Several original �orks have sho�ed that individu�
als �ith spontaneous type 1 ECG pattern of BS �arry a �orse 
prognosis than individuals �ith a sodium �hannel �lo�king 
test�indu�ed ECG pattern. A spontaneously a�normal ECG 
�arries an almost t�i�e higher risk of developing an arrhythmi� 
event during lifetime as �ompared to individuals �ith only 
drug�indu�ed features of BS. In a re�ent study, a spontaneous 
Type 1 Brugada ECG pattern in lead V2 (�ut not lead V1) �as 
�oth a prospe�tive and retrospe�tive independent predi�tor 
of VF episodes in Brugada syndrome. A �orre�ted QT (QT�) 
>460 ms in lead V2 has �een has �een asso�iated �ith an in�
�reased risk of arrhythmi� events. Larger daily flu�tuations of 
the r�J interval (interval from QRS onset to J�point) in leads 
V1, V2, and V6 have �een o�served in symptomati� than in 
asymptomati� patients �ith BS. A prolonged QRS duration 
in lead V2 (≥120 mse�) measured from standard 12�lead ECG 
has �een asso�iated �ith symptoms and �ould serve as a simple 
non�invasive risk marker of vulnera�ility to life�threatening 
ventri�ular arrhythmias in BS. An S �ave �idth ≥0.08 s in V1 
and ST�segment elevation ≥0.18 mV in V2 are highly spe�ifi� 
indi�ators of VF and �ere proposed as ne� �riteria for high 
risk patients �ith BS. Finally, the aVR sign, defined as R �ave 
≥0.3 mV or R/q ≥0.75 in lead aVR, has �een asso�iated �ith 
an in�reased risk of arrhythmi� events in su�je�ts �ith BS. The 
presen�e of late potentials is of prognosti� signifi�an�e for 
life�threatening events. The predi�tive value of indu�i�ility of 
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sustained ventri�ular arrhythmias during ele�trophysiologi�al 
study (EPS) still remains a matter of de�ate. Ho�ever, t�o 
meta�analyses and t�o large prospe�tive studied (FINGER 
and PRELUDE) failed to sho� any �enefit from VT/VF indu��
i�ility in risk stratifi�ation of patients �ith BS. More spe�ifi�
�ally, the PRELUDE study sho�ed that VT/VF indu�i�ility 
is una�le to identify high�risk patients, �hereas the presen�e 
of a spontaneous type 1 ECG, history of syn�ope, ventri�ular 
effe�tive refra�tory period <200 ms, and QRS fragmentation 
seem useful to identify �andidates for prophyla�ti� implanta�le 
�ardioverter defi�rillator (ICD). In a re�ent meta�analysis of 
30 prospe�tive studies in�luding 1.545 patients �ith BS ECG 
pattern, a history of syn�ope or SCD, the presen�e of a sponta�
neous type 1 Brugada ECG, and male gender predi�ted a more 
malignant natural history. These findings are no� supported 
�y the FINGER and PRELUDE registries. Asymptomati� 
individuals are at very lo� risk for arrhythmi� events.
The only effe�tive management of patients �ith definite 
BS is implantation of an ICD. Ho�ever, given the �ide varia�
tion in the in�iden�e of events, the appropriate indi�ation for 
ICD implantation remains un�ertain. Patients �ith a sponta�
neous or drug�indu�ed Type 1 Brugada ECG and a history of 
syn�ope or SCD should undergo ICD implantation. Based on 
the Se�ond Consensus Conferen�e on BS pu�lished on 2005, 
asymptomati� patients �ith a spontaneous Type 1 Brugada 
ECG or asymptomati� patients �ith a drug�indu�ed Type 1 
Brugada ECG and a family history of SCD should undergo 
ele�trophysiologi�al study (EPS) to guide the sele�tion of pa�
tients for ICD implantation. Ho�ever, a��ording to the results 
of FINGER and PRELUDE studies, VT/VF indu�i�ility at 
EPS does not provide any information in risk stratifi�ation, 
and therefore, the Consensus Conferen�e on BS should �e 
revisited. At present, there is no spe�ifi� pharma�ologi� treat�
ment to prevent SCD in patients �ith BS. Quinidine has �een 
sho�n to �e effe�tive in redu�ing arrhythmi� events, and a 
large prospe�tive study is no� running in order to test this ef�
fi�a�y. Finally, in a re�ent report, �atheter a�lation over right 
ventri�ular outflo� tra�t epi�ardium led to normali�ation of 
the Brugada ECG pattern and prevented VT/VF.
